AI Scent Detection Startup Anemo Labs Raises £700K

A London-based deeptech startup, Anemo Labs, has secured £700,000 in pre-seed capital to advance its groundbreaking work in olfactory artificial intelligence. The investment, spearheaded by Zinc and SFC Capital, with crucial backing from Innovate UK, will fuel the development of an 'electronic nose' capable of detecting disease markers through scent. This funding round positions Anemo Labs to refine its sensor technology and expand its AI's ability to interpret volatile organic compounds (VOCs) associated with various health conditions.

Founded in 2025 by Koye Sodipo, Anemo Labs is pioneering a novel approach to diagnostics by harnessing the power of smell. The company's core innovation lies in an advanced e-nose system that integrates sophisticated sensor hardware with machine learning algorithms. This synergy allows the AI to identify and classify minute concentrations of VOCs, the chemical signatures that give substances their distinct odors. The healthcare sector, a rapidly growing area for AI integration, is the initial focus, aiming to revolutionize non-invasive screening methods.

The immediate application targets the analysis of VOCs present in urine samples. This strategy aims to provide a passive and continuous screening mechanism, potentially identifying diseases at their earliest stages, even before overt symptoms manifest. This aligns with a significant trend in medtech towards preventative and early-detection solutions, a market segment projected to see substantial growth driven by an aging global population and increasing demand for personalized healthcare. Anemo Labs' technology could offer a less intrusive alternative to traditional diagnostic procedures.

Looking ahead, Anemo Labs envisions expanding its diagnostic capabilities to encompass a wider array of conditions where olfactory cues are clinically relevant. This includes potential applications for detecting urinary tract infections and certain types of cancer, areas where subtle changes in body odor have been observed. The company's scientific team, comprising PhD-level researchers in sensor chemistry and electronics, is working alongside clinical advisors to validate these diagnostic pathways, underscoring a robust, science-led development process.

Central to Anemo Labs' progress is its proprietary sampling platform, engineered to collect and meticulously label up to 5,000 distinct scent profiles daily. This extensive dataset is vital for training and refining the AI models. Early validation tests, utilizing the established Sniffin' Sticks olfactory testing protocol, demonstrated impressive accuracy, with the AI models correctly classifying scent categories in 84.15% of instances across 12 distinct categories. This level of precision highlights the potential of AI in interpreting complex sensory data.

The newly acquired funds will be strategically deployed to enhance the underlying sensor chemistry, scale up the company's capacity for smell data acquisition and annotation, and solidify clinical validation partnerships. By investing in these critical areas, Anemo Labs aims to accelerate its journey from research and development to market-ready diagnostic tools. The broader implications for the AI and healthcare sectors are significant, suggesting a future where artificial intelligence can augment human senses for critical health insights.